Plain-English translation of NCT06971614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to treat a specific type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) in people whose cancer has stopped responding to standard treatments like BCG or chemotherapy. The medication is injected directly into the bladder once a week for 6 weeks, followed by a rest period and then regular check-ups. If the treatment works well, patients may continue receiving the medication less frequently for up to 2 years.
Many people with advanced non-muscle-invasive bladder cancer don't respond well to current standard treatments, and some have to have their bladder removed. This trial exists to see whether this new medication can help people whose cancer is resistant to existing therapies, potentially offering them another chance to save their bladder and avoid surgery.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive weekly injections of the medication directly into your bladder for 6 weeks, followed by 6 weeks of observation. Then doctors will check whether the cancer has responded by examining your bladder with a camera and taking urine samples. If the treatment is working, you'll enter a maintenance phase where you receive the medication less often (once every 3 weeks) for up to 2 years, with regular monitoring visits every 3 months to make sure the cancer isn't returning.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States